DSIP for Sleep: Human Evidence and FDA Status

The name delta sleep-inducing peptide sounds like a promise. If you are struggling to sleep, however, the useful question is whether a treatment produces meaningful, reliable benefits for people like you. A name, a proposed mechanism or an old study cannot answer that alone.

DSIP has been studied in humans, but the small insomnia studies discussed here report mixed findings. Understanding what they measured helps you assess a sleep claim without assuming that a research preparation, a compounded product and an approved medicine are interchangeable.

What is DSIP?

Also called emideltide, DSIP is described as a nine-amino-acid peptide in the FDA's 2026 emideltide review. The assessment considered emideltide free base and acetate as substances proposed for use in compounding.

That identifies the subject of the review; it does not establish that a product will reliably improve sleep. Ask for the exact substance and preparation being discussed. The word peptide describes a type of molecule, not an approved sleep-treatment category.

What did the 1992 insomnia study find?

In a double-blind study of 16 people with chronic insomnia, researchers compared intravenous DSIP with placebo during a short laboratory stay. Some objective measurements favored DSIP, including sleep efficiency and the time taken to fall asleep. The researchers judged the effects weak, with some potentially explained by changes in the placebo group.

Subjective sleep quality did not improve. The authors concluded that short-term treatment was unlikely to provide major therapeutic benefit. Reporting only the favorable measurements would miss that important qualification.

Why do some earlier reports sound positive?

An earlier 1987 placebo-controlled insomnia study  investigated 14 middle-aged people under double-blind conditions. It reported improvements in night sleep and daytime performance after a short treatment period using intravenous DSIP.

Those findings deserve acknowledgment, but they do not settle the question. A small, selected group observed for a limited period cannot establish dependable long-term results across different patients or preparations. The contrast between this report and the later study is a reason to examine the evidence carefully, rather than selecting whichever conclusion matches a product advertisement.

Is a compounding review the same as drug approval?

No. FDA's July 2026 briefing stated that emideltide free base and acetate were not components of an FDA-approved drug. It evaluated proposed compounding substances; it was not approval of a sleep medicine.

An approved medicine has a defined product and approved uses. A committee discussion, a nomination or a research publication does not create that approval. If someone describes DSIP as FDA approved for sleep, ask for the specific approved product and indication rather than accepting a reference to a compounding review.

What safety uncertainties has FDA identified?

Current information appears in the FDA's emideltide safety entry. It identifies possible immune-reaction risks with certain routes, peptide impurities and difficulties characterizing the active ingredient. The agency says it lacks adequate safety information for the proposed route.

The entry is under substances whose nominations were withdrawn, rather than the active Category 2 table. Withdrawal is not approval or a finding that the concerns disappeared. Small older studies using an intravenous preparation cannot establish safety for every different route, formulation or duration of use.

What does the word compounded change?

It should prompt a separate conversation about the exact preparation. As the FDA's compounding questions and answers  explain, compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness and quality before marketing.

A prescription or a familiar ingredient name does not turn a compounded preparation into an approved sleep medicine. Nor does approval of some other peptide validate DSIP. Ask what evidence applies to the actual proposal, what remains uncertain and which established alternatives address your diagnosed problem.

What should a sleep evaluation include?

For persistent difficulty sleeping, the NHLBI guide to insomnia diagnosis  describes reviewing sleep patterns, daytime effects, medical history, medicines and substance use. Questions about snoring or waking while gasping can help identify reasons to investigate another sleep disorder.

Bring a record of bedtimes, awakenings, naps, daytime sleepiness and caffeine or alcohol use. Explain how long the problem has lasted and what you have already tried. Evaluation may require an examination or testing; a peptide discussion should not replace identifying the sleep problem.

Which established treatment can I ask about?

For adults with chronic insomnia disorder, the AASM's 2021 behavioral-treatment guideline  strongly recommends multicomponent cognitive behavioral therapy for insomnia, or CBT-I. It also advises against using sleep hygiene alone as the sole treatment.

CBT-I is a structured treatment approach that goes beyond general advice about sleep habits. Ask whether it fits your situation and how to access qualified care. Treatment choices should reflect the diagnosis, your health history and preferences, and the available care options.

Frequently asked questions

Does the name DSIP prove it increases deep sleep?

No. The name does not establish a clinical benefit. Read the actual study outcomes and limitations instead of treating a sleep-related name as a guarantee.

Is DSIP an FDA-approved insomnia medicine?

The FDA review discussed here did not identify emideltide as a component of an approved drug. A compounding assessment is a different process from approving a medicine for insomnia.

Do small human studies establish long-term safety?

No. Observations apply to the studied patients, preparation and follow-up period. They cannot resolve every safety question about a different compounded preparation or extended use.

Is CBT-I the same as sleep hygiene?

No. CBT-I combines structured treatment components. General sleep-habit advice alone is not equivalent to the multicomponent treatment recommended in the AASM guideline.

Discuss peptide questions through California telehealth

California residents can review our peptide therapy information  and contact SoCal Testosterone Clinic  about a consultation. The clinic currently provides California-only telehealth, with no in-person clinic appointments. Bring the specific product claim and research you want clarified. A consultation does not guarantee a prescription or establish that DSIP or any particular medicine is available.